Circulating tumor cells (CTCs) are cells that leave the primary tumor and are intravasated into the blood circulation system. A subset of those make it to other organs and are responsible for metastasis. iCellate’s CellMate platform is a CTC-based liquid biopsy for cancer cell enrichment, detection, and biomarker analysis via a simple blood draw.

In this seminar, you’ll learn:

From Helena Silva Cascales, senior scientist at iCellate Medical AB, how the isolation of whole-tumor cells provides a more comprehensive biomarker analysis, including genomic sequencing and multiplexed protein expression analysis.
From Kashyap Dave, principal scientist at iCellate Medical AB, how DNA from single CTCs can be amplified, sequenced, and analyzed to support malignancy designation and tissue of origin identification using classification analyses under development within Qiagen CLC Genomics Workbench.